Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited has announced the application for the quotation of 2,185,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company that specializes in developing cellular medicines. The company focuses on innovative therapies for inflammatory diseases, cardiovascular diseases, and back pain, aiming to address unmet medical needs in these areas.
YTD Price Performance: -46.61%
Average Trading Volume: 5,353,171
Technical Sentiment Signal: Hold
Current Market Cap: A$2.11B
See more data about MSB stock on TipRanks’ Stock Analysis page.